Literature DB >> 20217258

Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer.

Tomomi Yakabe1, Yuji Nakafusa, Kenji Sumi, Atsushi Miyoshi, Yoshihiko Kitajima, Seiji Sato, Hirokazu Noshiro, Kohji Miyazaki.   

Abstract

BACKGROUND: We evaluated the efficiency of CEA and CA19-9 as tools for diagnosing recurrence in the postoperative surveillance of colorectal cancer.
MATERIALS AND METHODS: A total of 227 patients who underwent curative resection for colorectal cancer between 1999 and 2003 at our hospital received complete follow-up according to the schedule determined prospectively. Using receiver operating characteristic (ROC) analysis, performance of postoperative values of CEA or CA19-9 for detecting recurrence was assessed.
RESULTS: The sensitivity (1.000) and specificity (0.978) of the postoperative values of CEA in the high preoperative CEA group were very high. Even in the normal preoperative CEA group, the area under the curve (AUC) of the ROC curve of CEA (0.740, 95% confidence interval [95% CI], 0.628-0.852) was significantly larger than 0.5 (P < 0.001). The postoperative values of CA19-9 showed high sensitivity (0.833) and specificity (0.900) in the high preoperative CA19-9 group, while the AUC of the ROC curve of the normal preoperative group was as small as 0.510 (95% CI, 0.376-0.644). In the high preoperative CA19-9 group, however, there was no significant difference between the AUC of CA19-9 (0.904, 95% CI, 0.786-1.000) and that of CEA (0.869, 95% CI, 0.744-0.994) (P = 0.334).
CONCLUSIONS: The measurement of CEA is an efficient way to detect recurrence. The efficiency of measuring CA19-9 for the purpose of detecting recurrence is low, especially in patients with a normal level of preoperative CA19-9. Even in patients with a high preoperative level of CA19-9, CEA might be able to fill the role of CA19-9.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217258     DOI: 10.1245/s10434-010-1004-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  33 in total

1.  Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Authors:  Ching-Wei D Tzeng; Aparna Balachandran; Mediha Ahmad; Jeffrey E Lee; Sunil Krishnan; Huamin Wang; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Peter W T Pisters; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

2.  Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.

Authors:  Eric I Marks; Matthew Brennan; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Impact of the post/preoperative serum CEA ratio on the survival of patients with rectal cancer.

Authors:  Tsukasa Hotta; Katsunari Takifuji; Shozo Yokoyama; Kenji Matsuda; Yoshimasa Oku; Toru Nasu; Junji Ieda; Naoyuki Yamamoto; Hiromitsu Iwamoto; Yoh Takei; Yuki Mizumoto; Hiroki Yamaue
Journal:  Surg Today       Date:  2014-02-07       Impact factor: 2.549

4.  Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.

Authors:  Yifan Peng; Zhiwei Zhai; Zhongmin Li; Lin Wang; Jin Gu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Characteristics and timing of recurrence during postoperative surveillance after curative resection for lung adenocarcinoma.

Authors:  Terumoto Koike; Tatsuya Goto; Akihiko Kitahara; Seijiro Sato; Masayuki Saitoh; Takehisa Hashimoto; Osamu Namura; Masashi Takahashi; Shin-Ichi Toyabe; Masanori Tsuchida
Journal:  Surg Today       Date:  2017-05-04       Impact factor: 2.549

6.  Cartilage oligomeric matrix protein is a prognostic factor and biomarker of colon cancer and promotes cell proliferation by activating the Akt pathway.

Authors:  Ting-Ting Liu; Xi-Sheng Liu; Meng Zhang; Xue-Ni Liu; Fu-Xiang Zhu; Fang-Ming Zhu; Si-Wen Ouyang; Shan-Bao Li; Chen-Long Song; Hui-Min Sun; Su Lu; Yu Zhang; Jun Lin; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-20       Impact factor: 4.553

Review 7.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

8.  Detection and Clinical Significance of DLC1 Gene Methylation in Serum DNA from Colorectal Cancer Patients.

Authors:  Ping-Ping Wu; Ji-Hong Zou; Ri-Ning Tang; Yao Yao; Cheng-Zhong You
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

Review 9.  Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations.

Authors:  Enikő Orosz; István Ember; Katalin Gombos; László Tóth; Ádám Tarpay; Ákos Pap; Szabolcs Ottó
Journal:  Pathol Oncol Res       Date:  2013-07-19       Impact factor: 3.201

10.  The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery.

Authors:  Ryosuke Okamura; Suguru Hasegawa; Koya Hida; Nobuaki Hoshino; Kenji Kawada; Kenichi Sugihara; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2016-08-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.